Revenio Group Corporation, Stock Exchange Release, October 14, 2020 at 21.45
Notice pursuant to chapter 9, section 5 of the securities market act
Revenio Group Corporation has October 13, 2020 received a notification of change
in holdings in accordance with Chapter 9, Section 5 of the Securities Markets
Act that The Capital Group Companies Inc’s share of the total number of shares
and voting rights in Revenio Group Corporation has decreased to less than five
per cent.
The Capital Group Companies Inc now holds 1.288.756 shares in Revenio Group
Corporation, which is 4.8399 per cent of the company's shares and voting rights.
The total number of Revenio Group Corporation's shares recorded in the trade
register is 26.627.557.
Revenio Group Corporation
For further information, please contact:
CFO Robin Pulkkinen, tel. +358 50 505 9932
robin.pulkkinen@revenio.fi
www.revenio.fi
DISTRIBUTION:
Nasdaq Helsinki Ltd
Financial Supervisory Authority
Main media
www.revenio.fi
Revenio Group in brief
Revenio, a health technology group operating in the international markets, is
one of the global leaders in ophthalmic appliances. Revenio Group's ophthalmic
diagnostic solutions include intraocular pressure measurement devices under the
Icare brand and retinal imaging devices. The main tool for the detection and
diagnosis of glaucoma and its monitoring during treatment are intraocular
pressure measurement (tonometry), retinal imaging, and visual field tests
(perimetry).
The Revenio Group consists of Icare Finland Oy, Icare USA Inc., Revenio Italy
S.R.L, CenterVue SpA, Revenio Research Oy, Done Medical Oy and Oscare Medical
Oy.
The common denominators of Revenio's business operations include patient
-oriented screening, follow-up and the global need to make cost savings through
preventive health care. Revenio seeks vigorous growth in health technology.
Revenio aims to develop even more efficient and easily adopted methods for the
early-stage detection of diseases with significance for public health. The aim
is to improve the quality of life through health technology solutions which
enable more effective diagnostics. Revenio Group’s focus is on the early
detection of glaucoma, diabetic retinopathy and macular degeneration, and the
monitoring of these during the treatment process. Revenio Research concentrates
on the commercialization of systems supporting the diagnosis of and treatment
planning for skin cancer and asthma.
In 2019, Revenio Group's net sales totalled EUR 49.5 million, with its net
operating profit standing at 25.5 %. Revenio Group Corporation is listed on
Nasdaq Helsinki.